ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Predictors of vision-threatening proliferative diabetic retinopathy in the fellow eye after unilateral vitrectomy: a clinical and imaging-based study.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo identify clinical and imaging factors associated with vision-threatening proliferative diabetic retinopathy (VT-PDR) in the fellow eye of patients undergoing vitrectomy for VT-PDR in one eye.
methodsThis retrospective cohort study included patients with type 2 diabetes mellitus who underwent vitrectomy for VT-PDR-defined as moderate-to-severe vitreous haemorrhage, tractional retinal detachment involving or threatening the macula, or extensive neovascularization-between January 2017 and December 2022. Clinical and imaging data including diabetic retinopathy severity scale (DRSS), presence of predominantly peripheral lesions (PPL), and VT-PDR subtype in the operated eye, were evaluated. Cox proportional hazards model was used as the primary analysis, supported by Kaplan-Meier survival analysis, multivariate logistic regression, and sensitivity analyses.
resultsAmong 152 patients (mean age 50.1 ± 9.8 years), 96 patients (63.2%) developed VT-PDR in the fellow eye during a mean follow-up of 39.3 ± 23.4 months. Cox regression identified younger age (HR 0.822 per 5-year increase, 95% CI 0.726-0.930, p = 0.002), higher DRSS in the fellow eye (HR 1.033 per point, 95% CI 1.003-1.064, p = 0.029), and PPL (HR 1.819, 95% CI 1.095-3.022, p = 0.021) as independent predictors of progression. Kaplan-Meier curves confirmed significantly shorter time to VT-PDR events in eyes with these risk factors (all p < 0.05).
conclusionYounger age, advanced DRSS, and PPL are independent risk factors for fellow-eye VT-PDR. Early identification of these risk factors may help guide close monitoring and timely intervention to prevent vision loss in the fellow eye. KEY MESSAGES: WHAT IS KNOWN : Patients undergoing vitrectomy for proliferative diabetic retinopathy (PDR) in one eye remain at risk for vision-threatening PDR (VT-PDR) in the fellow eye. Prior studies have mainly assessed systemic factors or DR severity, with limited evaluation of widefield imaging features. WHAT IS NEW: Younger age, higher diabetic retinopathy severity scale (DRSS) scores, and predominantly peripheral lesions (PPL) on widefield imaging independently predict fellow-eye VT-PDR progression. Integrating systemic, clinical, and imaging factors enables improved risk stratification and highlights the need for closer surveillance in high-risk patients.
Indexed as
Identifiers
41642304What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.